Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.49 |
| ▸ | CYP2A13 | Q16696 | 5/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL793450 | 0.81 | HRH3 (0.56) | CXCR4CYP2A13HRH3MEN1KMT2A | |
| SCHEMBL7377506 | 0.81 | HRH3 (0.48) | HRH3KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL3512357 | 0.80 | CXCR4 (0.47) | CXCR4CYP2A13HRH3MEN1KMT2A | |
| SCHEMBL27238744 | 0.77 | CXCR4 (0.53) | CXCR4CYP2A13HRH3NPC1RAB9A | |
| SCHEMBL27144744 | 0.77 | CXCR4 (0.53) | CXCR4CYP2A13HRH3MEN1KMT2A | |
| SCHEMBL798244 | 0.75 | HRH3 (0.49) | CXCR4CYP2A13HRH3MEN1KMT2A | |
| SCHEMBL20908819 | 0.75 | CNR2 (0.51) | CXCR4CYP2A13HRH3MEN1KMT2A | |
| SCHEMBL27238760 | 0.75 | CXCR4 (0.50) | CXCR4CYP2A13HRH3NPC1RAB9A | |
| SCHEMBL6033723 | 0.75 | ABL1 (0.53) | MAPT | |
| SCHEMBL21777045 | 0.74 | CYP2A13 (0.48) | CXCR4CYP2A13HRH3NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117940433-A | Quinoline furan derivative and application thereof | 瑞石生物医药有限公司 | 2024-04-26 | — | — | CN | disclosed |
| WO-2023025298-A1 | QUINOLINOFURAN DERIVATIVE AND USE THEREOF | 瑞石生物医药有限公司 | 2023-03-02 | — | — | WO | disclosed |
| EP-1685124-A1 | SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LTD. (GB) | 2006-08-02 | — | — | EP | disclosed |
| US-20050197342-A1 | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain | HOLLINGWORTH GREGORY J (GB) | 2005-09-08 | — | — | US | disclosed |
| WO-2005047279-A1 | SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197342-A1 | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain | OPRL1, OPRK1, CNR1 | CXCR4 381/4885CYP2A13 1163/4885HRH3 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.